Submissions for posters are now closed. Posters abstracts received will be reviewed by the ECRD 2020 Poster Committee and notifications will be sent to all poster authors by 6th March 2020.
- Poster abstract submissions accepted in English only.
- Poster abstract submissions are limited to 300 words.
- You may be co-author of any number of poster abstracts but presenting author of only one.
- Please indicate if your abstract has already been presented at other events.
Posters will be scored using the following criteria:
1) Relevance of the topic to rare diseases
- Relevance, currency (how new/recent/up-to-date the information/study is), significance and appropriateness to the conference/theme
- Practical application to the field
2) Quality of content
- Clarity of the title
- Concision, coherence and clarity of content (summary of purpose and methodology, results, conclusions, next steps/practical application, etc.)
- Methodology of the given study/poster
- Originality (posters can be presented at other conferences prior to ECRD 2020)
- Commercial product promotion
- Disregard for above guidelines
- Submission after the deadline
- Incorrect submission channel (must use the online form)
Posters abstracts will be reviewed by the ECRD 2020 Poster Committee in February 2020. Notifications will be sent to all poster authors by 6th March 2020. Please note that poster applicants are not exempt from paying the full registration fees to attend ECRD 2020.
The future of diagnosis: new hopes, promises and challenges
Improving the experiences of genetic counselling
Examples of novel methods such as co-production in diagnosis research and care
Ethical and societal aspects of a diagnosis for all
Examples of advances in Newborn screening programmes
Our values, our rights, our future: shifting paradigms towards inclusion
Information and statistical data (including surveys, censuses, administrative data, literature, reports, and studies) related to the exercise of the right to health of persons living with a rare disease; with particular emphasis on comparative studies across the EU or the new EU member states (EU13);
Examples of implementation of patient’s rights in cross-border care across Europe (good practices and policies, pilot projects at local, national and regional level);
Examples of social security schemes and welfare systems that address the specific needs of persons living with a rare disease;
Examples of and studies on involvement of persons living with a rare disease and their representative organisations in the design, planning, implementation and evaluation of health and social policies, programmes and services;
Innovative services, policies or practices to implement integrated care for people living with a rare disease.
Share, Care, Rare: Transforming care for rare diseases by 2030
ePAG patient advocates as well clinicians involved in the European Reference Networks are invited to present their good practices and initiatives in this area.
When therapies meet the needs: enabling a patient-centric approach to therapeutic development
Knowledge generation through Real World Evidence collection;
Innovative approaches in repurposing (i.e therapies available, accessible and affordable to patients);
Disregarded diseases: development in yet unexplored medical areas;
Alternative business models for therapies development in rare diseases;
Sustainable patient engagement.
Achieving the triple A’s by 2030: Accessible, Available and Affordable Treatments for people living with a rare disease
New approaches to medicines price setting
Examples of cross country collaboration on assessment / procurement of therapies
Alternative model of R&D for rare diseases
The digital health revolution: hype vs. reality
Examples of how technology (e.g. artificial intelligence) is influencing the management of rare diseases in areas such as patient care, monitoring and development of therapies/products;Examples of innovative legal and ethical solutions for data collection and governance;
Examples of how patients have co-created new innovation and technology;
Reports or examples of international patient data collection/connection;
Technology examples that are inclusive and accessible for people with rare diseases;
Examples of initiatives that:
- allow patients to collect or report their own data
- enable a quicker/more accurate diagnosis
- provide a positive impact on the daily lives/quality of life of patients and their carers through technology
- allow patients to connect with others patients
help to reach more patients, especially those who live in areas where there is no or little infrastructure for rare diseases
Rare Disease Patient Groups Innovations
Innovative strategies/approaches/services or projects which could potentially be useful to other patient groups/healthcare professionals/academia or which deserve to be promoted internationally and recognised by national and European authorities.